Celcuity (CELC) Stock Forecast & Price Target

Celcuity is viewed positively because gedatolisib has already demonstrated clinically meaningful efficacy and tolerability in the Phase 3 VIKTORIA-1 program, with the PIK3CA mutant cohort doubling the likelihood of progression-free survival versus alpelisib plus fulvestrant and the PIK3CA wild-type indication already FDA-approved. Its commercial case is strengthened by REVTORPYK pricing of about $10,000 per vial, or roughly $30,000 per cycle, plus an estimated 20% gross-to-net discount, while launch readiness includes 1,000+ KOLs/community oncologists engaged, 250+ key accounts, EAP shipping, and a second manufacturing site coming online. Financially, the company ended 2Q26 with $754 million in cash and runway into >2029, giving it ample flexibility to fund the late 3Q26 launch, the planned 3Q26 sNDA submission, and ongoing VIKTORIA-2 and CELC-G-201 development.

Celcuity is a high-risk development-stage biotechnology company whose negative outlook stems from the binary nature of gedatolisib’s clinical and regulatory path, where failure in ongoing or future trials could sharply impair value. Although VIKTORIA-1 has completed enrollment and reported results for PIK3CA WT tumors, the broader program still faces uncertainty in PIK3CA MT, VIKTORIA-2, and CELC-G-201, while mCRPC remains unproven and clinical collaborations can be terminated. Commercially, Revtorpyk enters a crowded HR+/HER2- mBC market with no guarantee of adoption or reimbursement, and the company is likely to need additional equity financing, raising dilution risk for existing shareholders.